Cargando…

Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept

Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the larges...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Joana, Marques, Cláudia, Nunes, Cláudia, Sarraguça, Mafalda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647364/
https://www.ncbi.nlm.nih.gov/pubmed/37958633
http://dx.doi.org/10.3390/ijms242115648
_version_ 1785135089828495360
author Gonçalves, Joana
Marques, Cláudia
Nunes, Cláudia
Sarraguça, Mafalda
author_facet Gonçalves, Joana
Marques, Cláudia
Nunes, Cláudia
Sarraguça, Mafalda
author_sort Gonçalves, Joana
collection PubMed
description Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the largest public health problems. The engineering and development of new drugs is a complex process; therefore, the modification and enhancement of the drugs already marked is a better and faster solution. Ethambutol (ETB) is an antimycobacterial drug used to treat tuberculosis; however, it is highly hygroscopic and is sparingly soluble in water. Therapeutic Deep Eutectic Solvents (THEDESs) are known to improve drug solubility, permeability, and hygroscopicity, among others. In this study, three THEDESs of ETB were synthesized with sucralose, glucose and glycerol and then encapsulated in nanostructured lipid carriers to improve their stability. This work is a proof of concept on the possibility of encapsulating the THEDESs, and results show that the encapsulation of ETB is possible, yielding formulations with a loading capacity superior to 8.5% and able to incorporate THEDESs and not just ETB.
format Online
Article
Text
id pubmed-10647364
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106473642023-10-27 Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept Gonçalves, Joana Marques, Cláudia Nunes, Cláudia Sarraguça, Mafalda Int J Mol Sci Article Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the largest public health problems. The engineering and development of new drugs is a complex process; therefore, the modification and enhancement of the drugs already marked is a better and faster solution. Ethambutol (ETB) is an antimycobacterial drug used to treat tuberculosis; however, it is highly hygroscopic and is sparingly soluble in water. Therapeutic Deep Eutectic Solvents (THEDESs) are known to improve drug solubility, permeability, and hygroscopicity, among others. In this study, three THEDESs of ETB were synthesized with sucralose, glucose and glycerol and then encapsulated in nanostructured lipid carriers to improve their stability. This work is a proof of concept on the possibility of encapsulating the THEDESs, and results show that the encapsulation of ETB is possible, yielding formulations with a loading capacity superior to 8.5% and able to incorporate THEDESs and not just ETB. MDPI 2023-10-27 /pmc/articles/PMC10647364/ /pubmed/37958633 http://dx.doi.org/10.3390/ijms242115648 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gonçalves, Joana
Marques, Cláudia
Nunes, Cláudia
Sarraguça, Mafalda
Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title_full Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title_fullStr Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title_full_unstemmed Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title_short Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
title_sort therapeutic liquid eutectic solvents in lipid nanoparticles as drug vehicles—a proof of concept
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647364/
https://www.ncbi.nlm.nih.gov/pubmed/37958633
http://dx.doi.org/10.3390/ijms242115648
work_keys_str_mv AT goncalvesjoana therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept
AT marquesclaudia therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept
AT nunesclaudia therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept
AT sarragucamafalda therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept